Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.

Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, Khoury HJ, Fabbro D, Gilliland DG, Bergsagel PL, Taunton J, Polakiewicz RD, Chen J.

Cancer Cell. 2007 Sep;12(3):201-14.

2.

New insights into RSK activation and hematopoietic cancer.

Cuadrado A, Nebreda AR.

Cancer Cell. 2007 Sep;12(3):187-9.

3.

Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.

Kang S, Dong S, Guo A, Ruan H, Lonial S, Khoury HJ, Gu TL, Chen J.

J Biol Chem. 2008 Feb 22;283(8):4652-7. Epub 2007 Dec 21.

4.

Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation.

Kang S, Elf S, Dong S, Hitosugi T, Lythgoe K, Guo A, Ruan H, Lonial S, Khoury HJ, Williams IR, Lee BH, Roesel JL, Karsenty G, Hanauer A, Taunton J, Boggon TJ, Gu TL, Chen J.

Mol Cell Biol. 2009 Apr;29(8):2105-17. doi: 10.1128/MCB.00998-08. Epub 2009 Feb 17.

5.

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, Dong Z, Berquin IM, Roux PP, Dunn SE.

Breast Cancer Res. 2008;10(6):R99. doi: 10.1186/bcr2202. Epub 2008 Nov 27.

6.

A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1.

Frödin M, Jensen CJ, Merienne K, Gammeltoft S.

EMBO J. 2000 Jun 15;19(12):2924-34.

7.
8.

ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.

Oh YT, Liu X, Yue P, Kang S, Chen J, Taunton J, Khuri FR, Sun SY.

J Biol Chem. 2010 Dec 31;285(53):41310-9. doi: 10.1074/jbc.M110.153775. Epub 2010 Nov 2.

9.

PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells.

Xu L, Su L, Liu X.

Mol Cancer Ther. 2012 Oct;11(10):2174-82. doi: 10.1158/1535-7163.MCT-12-0602. Epub 2012 Jul 30.

10.
11.

ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15.

Vaidyanathan H, Opoku-Ansah J, Pastorino S, Renganathan H, Matter ML, Ramos JW.

Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19837-42. Epub 2007 Dec 6.

12.

Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.

Liu K, Cho YY, Yao K, Nadas J, Kim DJ, Cho EJ, Lee MH, Pugliese A, Zhang J, Bode AM, Dong Z, Dong Z.

J Biol Chem. 2011 Jan 21;286(3):2057-66. doi: 10.1074/jbc.M110.147306. Epub 2010 Nov 22.

13.

Ribosomal S6 kinase 2 interacts with and phosphorylates PDZ domain-containing proteins and regulates AMPA receptor transmission.

Thomas GM, Rumbaugh GR, Harrar DB, Huganir RL.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15006-11. Epub 2005 Oct 10.

14.

Phosphorylation of H2AX at Ser139 and a new phosphorylation site Ser16 by RSK2 decreases H2AX ubiquitination and inhibits cell transformation.

Zhu F, Zykova TA, Peng C, Zhang J, Cho YY, Zheng D, Yao K, Ma WY, Lau AT, Bode AM, Dong Z.

Cancer Res. 2011 Jan 15;71(2):393-403. doi: 10.1158/0008-5472.CAN-10-2012. Epub 2011 Jan 11.

15.

p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.

Elf S, Blevins D, Jin L, Chung TW, Williams IR, Lee BH, Lin JX, Leonard WJ, Taunton J, Khoury HJ, Kang S.

Blood. 2011 Jun 23;117(25):6885-94. doi: 10.1182/blood-2010-10-315721. Epub 2011 Apr 28.

16.

RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.

Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, Kiyota M, Nakayama R, Mizutani S, Chinen Y, Sakamoto N, Matsumoto Y, Horiike S, Shiotsu Y, Iida S, Taniwaki M.

Mol Cancer Ther. 2012 Dec;11(12):2600-9. doi: 10.1158/1535-7163.MCT-12-0605. Epub 2012 Sep 25.

17.

Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.

Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK.

Blood. 2000 Feb 1;95(3):992-8.

18.

p90 ribosomal S6 kinase 2 is associated with and dephosphorylated by protein phosphatase 2Cdelta.

Doehn U, Gammeltoft S, Shen SH, Jensen CJ.

Biochem J. 2004 Sep 1;382(Pt 2):425-31.

19.

Regulation of NHE3 by lysophosphatidic acid is mediated by phosphorylation of NHE3 by RSK2.

No YR, He P, Yoo BK, Yun CC.

Am J Physiol Cell Physiol. 2015 Jul 1;309(1):C14-21. doi: 10.1152/ajpcell.00067.2015. Epub 2015 Apr 8.

20.

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK.

Blood. 2005 Apr 1;105(7):2941-8. Epub 2004 Dec 14.

Supplemental Content

Support Center